RENPHO Expands Smart Scale Lineup Amid Rising GLP-1 Usage

The company’s latest additions, the MorphoScan Aspire and MorphoScan Lite, join the existing Nova and Base models to create a tiered ecosystem of wellness tracking. This expansion comes as recent Gallup polling indicates that 11% of U.S. adults are now using GLP-1 medications, a significant increase from 3% in 2024. For these users, monitoring shifts in muscle mass and body fat percentage is becoming as critical as tracking total weight loss.

All four devices utilize 8-electrode, dual-frequency Bioelectrical Impedance Analysis (BIA) technology to measure over 50 metrics, including visceral fat, metabolic age, and segmental muscle analysis. While the entry-level Lite ($129.99) focuses on basic tracking, the new Aspire ($169.99) introduces Wi-Fi connectivity and a larger display for more seamless data syncing. The flagship Nova remains the most advanced option, featuring voice-guided measurements and a full-color handle display, a tool already utilized by over 300 clinicians across the U.S. to help patients identify meaningful health trends.